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Abstract
A one-day workshop on Burkitt lymphoma (BL) was held at the 9th African Organization for Research and Training
in Cancer (AORTIC) conference in 2013 in Durban, South Africa. The workshop featured 15 plenary talks by delegates
representing 13 institutions that either fund or implement research on BL targeting AORTIC delegates primarily
interested in pediatric oncology. The main outcomes of the meeting were improved sharing of knowledge and
experience about ongoing epidemiologic BL research, BL treatment in different settings, the role of cancer registries
in cancer research, and opportunities for African scientists to publish in scientific journals. The idea of forming a
consortium of BL to improve coordination, information sharing, accelerate discovery, dissemination, and translation
of knowledge and to build capacity, while reducing redundant efforts was discussed. Here, we summarize the
presentations and discussions from the workshop.
Introduction
On November 20, 2013, scientists from 13 institutions
held a one-day pre-conference workshop during the 9th
African Organization for Research and Training in
Cancer (AORTIC) conference in Durban, South Africa
(Additional file 1: Table S1) [1]. The workshop was mo-
tivated by a positive response to a successful 3-hour satel-
lite meeting organized by Epidemiology of Burkitt
Lymphoma in East-African Children and Minors (EMBLEM)
at the 8th AORTIC conference in 2011 in Cairo, Egypt to
highlight research sponsored by the Intramural Research
Program of the National Cancer Institute (NCI) in East
Africa and in Ghana. The workshop objectives were to
highlight Burkitt Lymphoma (BL) research in East Africa,
one of the regions with the highest recorded rates of BL,
and highlight the seminal contribution of BL research to
cancer research in general and in Africa in particular. The
workshop aimed to increase awareness about ongoing
funded BL research, including epidemiology, treatment,
and immunology; and to highlight the importance of
cancer registration, capacity-building, and scientific
publication in BL research in East Africa. The workshop
also provided a platform to discuss ways to improve
collaboration. Here we summarize the presentations,
discussions, and conclusions from the workshop.
The EMBLEM study
The workshop began with a presentation by Dr. Mbulai-
teye about the objectives, design, and timeline of the
EMBLEM Study (http://emblem.cancer.gov/). EMBLEM is a
biomolecular-epidemiologic study funded by the Intramural
Research Program of the National Cancer Institute (NCI) in
collaboration with local investigators in Uganda, Tanzania,
and Kenya (Figure 1). The objectives are to investigate the
link between infections with Plasmodium falciparum (Pf)
malaria, Epstein-Barr virus (EBV) and genetic risk factors
with BL. Since BL is the most common childhood cancer,
and Pf malaria, the putative cause, is the leading cause of
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morbidity and mortality in East Africa, findings from
EMBLEM could influence the scope and direction of cancer
research, care, prevention in East Africa. Historically,
BL research in Africa has influenced oncology practice [2],
including the first effective use of chemotherapy for BL,
first demonstrated in the East Africa [3], and then used
elsewhere and for other types of cancer [4]. Those early
studies showed the value of combination therapy and
CNS prophylaxis [5]. The uneven geographical patterns of
BL, notably high incidence in low-lying humid areas
in Africa suggested infectious etiology [6] and led to
the discovery in 1964 of Epstein-Barr virus (EBV) [7] as
the first human virus associated with a human cancer [8].
Today, EBV is designated as a Class 1 carcinogen for
BL and is implicated in several other cancers [9].
EBV cooperates with co-factors, particularly Pf malaria
[10], which was implicated based on correlational
studies of the geographical distribution of Pf malaria with
that of BL. Recent studies using anti-malaria antibody
assays are providing strong evidence for a role of malaria
in BL [11]. The results from these studies are difficult
to interpret because antibody levels may change after
disease onset (i.e., reverse causality bias). To overcome
this limitation, some investigators have measured genetic
polymorphisms in the hemoglobin gene that confer
resistance to severe fatal forms of malaria among
heterozygotes [12] to investigate the link between
malaria and BL. Genetic polymorphisms are ideal because
they are not subject to reverse causality bias and their dis-
tribution is governed by Mendelian randomization in the
population [13]. Only three small studies, all conducted
40 years ago in Nigeria [14], Uganda [15] and in Ghana
[16], have used this approach. They measured
hemoglobin electrophoretic patterns for the sickle cell
trait, which is associated with 70-90% protection from
severe malaria [17], in cases and controls. In the
study conducted in Nigeria, the frequency of the
sickle cell trait in 95 BL cases was half that found in
320 age- and sex-matched hospital controls [14]. However,
these results were not replicated in the other two studies
conducted in Uganda (36 cases and controls) [15] or in
Ghana (110 cases and 110 controls) [16] or in a recent
Figure 1 Map of East Africa showing six regions of the EMBLEM study area.
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study that was conducted in Kenya looking at 306 cases
and 537 ethnically matched controls [18]. These inconsist-
ent results do not invalidate the genetic approach because
the sickle cell trait may account for only 2% of the
malaria risk whereas genetic factors [19] account for
25% of malaria risk [20]. Thus, further studies are
needed to evaluate effects of multiple genes simultan-
eously and also take into account epistatic (positive and
negative) relationships between genes [19] to obtain
valid results. One objective of EMBLEM is to enrol
1500 BL cases from six rural regions in East Africa
where malaria transmission is holoendemic year round
[21] and two healthy location-matched controls per BL
case. The study will compare the cases and controls for 44
polymorphisms in 25 genes that are associated with Pf
malaria resistance [21]. In secondary analyses, association
of being a case with tag SNPs in the 25 genes will be eval-
uated to identify associations with non-candidate SNPs
(SNPs with no association with malaria disease). Dr.
Mbulaiteye noted replication of EMBLEM findings is
needed and called for other studies to be conducted in
similar settings, particularly in West Africa. He empha-
sized the importance of standardization of protocols
through collaboration to accelerate the pace of discovery,
replication, and translation, with the ultimate objective be-
ing to improve care and prevent BL.
Dr. Tobias Kinyera, EMBLEM Study Coordinator in
Uganda, reviewed the recent epidemiology of BL in Uganda.
He noted that the geographical patterns of incidence since
2000 mirror the historical patterns noted 40 years ago. The
incidence was lowest (0.1 cases per 100,000 children) in
Western Uganda and highest (2–15 cases per 100,000) in
northern Uganda [22]. However, while BL in the 1960s was
typically described as affecting jaws [23], the predominant
presentation today was mostly abdominal with or without
facial tumors [22]. Similar changes in anatomic site presen-
tation have been reported in Ghana [24], but the reasons
underlying these changes in predominate anatomic presen-
tation are unknown. He speculated that greater availability
of ultrasound, which provides more accurate information
about anatomic site involvement in the abdomen than was
possible using only clinical examination [25], might be re-
sponsible. Dr. Kinyera reported that the EMBLEM study is
being implemented in northern Uganda and that the cases
spotted in that region are referred to two local hospitals
with the capacity to diagnose and treat BL. To increase case
spotting in the region, EMBLEM has trained local health
workers and community stakeholders to increase their
awareness about BL and to encourage them to refer the
cases to the study hospitals for biopsy, histological diagnosis
and early treatment [26]. These procedures (spotting and
referral) have been integrated within the local community
health system (the main stakeholder) workflow. The
procedures were leading to broad-based improvements in
community engagement [21], diagnostic pathology [27],
and consistent use of protocol-based treatment for BL [26].
In concluding remarks, Dr. Kinyera noted that basic labora-
tory upgrades implemented to facilitate research sample
collection and long-term storage have enabled fieldwork to
be conducted in the rural areas of northern Uganda. To
date, 427 potential BL cases have been spotted and 220 of
them have been enrolled into the study. During the same
period, 1201 location-matched controls had been enrolled.
Dr. Esther Kawira, EMBLEM Study Co-PI in Tanzania,
reported that infrastructure improvements similar to those
described in Uganda had also been implemented to support
EMBLEM scientific research in rural Tanzania. These
include high-speed internet to support communication,
data faxing and access to the EMBLEM share portal for
secure transfer of sensitive research data, study protocol
archives; basic research equipment such as ultra-low
freezers, QBC hematology analyzers, and bench-top centri-
fuges. In addition, the staff was trained in good clinical and
laboratory practice. Dr. Kawira noted that an analysis of
historical BL data had revealed that BL incidence patterns
(2000 to 2010) in northern Tanzania had not changed
much from 40 years ago and the incidence varied from 2
cases per 100,000 in the Mwanza Region to 22 cases per
100,000 in Tarime in the Mara Region [28]. An unexpected
finding was that the incidence of BL fell between 2005 to
2009, the reasons for which were not clear [28]. To date
298 potential BL cases have been spotted and 60 of these
were eligible and have been enrolled. Control enrollment is
scheduled to begin in 2014.
Dr. Constance Tenge, EMBLEM Co- PI in Kenya,
reported on EMBLEM in Kenya. She noted that an
environment of relative competition characterized the
work in Kenya since there were several groups who
had initiated or had plans to initiate BL studies in
overlapping geographical areas but with little coordination
across them. This has created unique challenges about how
to present a simple and positive message about BL to the
community. Consistent with the principle of community
engagement [21,26], EMBLEM had established field sites at
Homa Bay and Webuye District Hospitals, and established
a contract with the Academic Model Providing Access to
Healthcare (AMPATH) [29] at Moi Teaching and Referral
Hospital (MTRH) to use their laboratories for long-term
sample storage and another contract with MTRH for
histological diagnosis of BL. To date, 258 potential BL cases
have been spotted and 90 of these have been enrolled.
Control enrollment is scheduled to begin in 2014.
Dr. Kishor Bhatia, EMBLEM Co-PI and adjunct
Investigator in the Division of Cancer Epidemiology and
Genetics at NCI, gave an overview titled “Molecular
studies: What is possible within EMBLEM structure?”
He noted that the design of EMBLEM to enroll a large
number of cases from diverse geographical areas is an
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excellent platform for molecular studies to investigate
host-pathogen interaction in BL carcinogenesis [30,31].
The use of biopsy confirmed cases and collection of
residual tissue to verify the diagnosis of BL was a strength
[27], which had already enabled EMBLEM to contribute
to one study of functional genomics of BL [30]. Tissues
from EMBLEM were used to confirm mutations affecting
the transcription factor TCF3 (E2A) or its negative
regulator ID3. These genes influence the signaling of the
pro-survival phosphatidylinositol-3-OH kinase pathway
that had been discovered through the study of BL tumor
cell lines. These studies have indicated substantial differ-
ences in the percentage of mutated CCND3 by BL
subtype (38% CCND3 in sporadic BL vs. 1.8% in en-
demic BL) [30]. These results pave the way to use
high-resolution SNP arrays to study endemic BL as
has been done in sporadic BL [30,32,33], and point to
exciting possibilities for discovery of molecular abnormal-
ities that initiate or drive malignant growth in African
BL cases and the possible interaction with EBV [34].
Furthermore, high-resolution SNP array studies could
shed light on the molecular heterogeneity of BL and
suggest novel ways for molecularly targeted treatment of
BL [2] or lead to discovery of non-human sequence data
suggesting novel viral sequences or EBV variants that may
be correlated with BL tumor development [2].
Dr. Peter Odada, Senior Researcher at KEMRI and
EMBLEM Co-PI in Kenya, discussed the relationship
between malaria and BL in Kenya [35]. Given the negative
impact of malaria on health and nutrition, he speculated
that micronutrient deficiency compounded by malaria
infection might influence the risk of BL. In support of this
idea, he shared the results from his recent study in Kenya
showing that children living in high BL incidence areas
were more likely to have lower Glutathione peroxidase
(GPx) levels and higher EBV viral loads than children
from low BL incidence areas [36].
Dr. Kenneth Simbiri, Instructor of Microbiology and
Immunology at SUNY Upstate Medical University,
presented a paper titled “Cancer in Africa in 21st
Century: Paradigm Shift”. He reviewed recent literature
about associations between viruses and cancer and noted
the unacceptably high burden of infection-associated
cancers in Africa, including cervical, vulvar, conjunctival,
and anal [8]. Given the overlap of high HIV rates in Africa
with many virally associated cancers, he stressed the need
for studies to be conducted about infectious agents
causing cancer and utilizing that knowledge in cancer
control efforts in Africa [37-39].
Dr. Juliana Otieno, Pediatrician and Chief Administrator
of Jaramogi Oginga Odinga Teaching and Referral
Hospital (JOOTRH) in Kisumu, Kenya presented a paper on
Burkitt lymphoma incidence in Western Kenya: experience
from JOOTRH. Dr. Ann Moormann, Associate Professor at
the University of Massachusetts Medical School,
Worcester, MA, USA and a Visiting Scientist at KEMRI,
presented a paper on EBNA T cell responses in BL in
Kenya. The details of these presentations are not included
in this report as they contain unpublished data.
Treatment of Burkitt lymphoma in South Africa
Dr. Cristina Stefan, Professor and Head of Pediatric
Oncology, University of Stellenbosch presented her
data on “BL in HIV positive children in South Africa
during 1990 – 2008 from the South African pediatric
cancer registry” [40,41]. Dr. Stefan reported that the
survival rate for Hodgkin lymphoma was 45.8% in
HIV positive children compared to a survival rate of
80% in HIV-negative children. Likewise, mortality in HIV
positive children with BL was high due to toxicity of
treatment, and up to 10% could not be treated because of
unstable clinical conditions. Dr. Stefan noted that although
all cases of BL in South Africa were histologically,
cytogenetically, or immunohistochemically tested, there
was still a need for consistency across diagnostic types
since there is no “gold standard” for BL diagnosis [27].
She expressed willingness to share tissues from her cases
for genetic studies of BL.
Cancer registration as a catalyst for research in Burkitt
lymphoma
Dr. Robert Newton, who has longstanding research
experience conducting cancer research in sub-Saharan
Africa and is the representative of the International
Agency for Research on Cancer (IARC) Global Initiative
for Cancer Registration in Africa, presented an overview
about the role of cancer registries in cancer research.
Focusing on BL as a model disease, he illustrated the
challenges of cancer registration. He noted that the first
challenge for cancer research and registration is defining
the cancer of interest using reproducible criteria. Histology
is the typically accepted standard for diagnosis of cancer,
including of BL, but the lack of high-quality histology in
Africa undermines the confidence in African cancer data
[27,42]. Improvements in the quality of formalin-fixed
and formalin-embedded tissues would enable the use
of immunohistochemistry and cytogenetics for diagnosis,
particularly of BL, and improve confidence in the data.
The second challenge is identifying all the cases of cancer
that occur in a well-defined population. To generate
accurate cancer statistics (incidence and mortality), the
population at risk that is covered by a particular registry
needs to be defined, and all the cases occurring in the
population need to be identified. Both definition of
population at risk and obtaining complete cancer data
are difficult to achieve in Africa given the lack of accurate
census data for most countries [43,44], and the low level
of service provision or access. Together, these difficulties
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introduce uncertainty in cancer statistics from Africa.
Dr. Newton noted that registration of childhood cancers,
which are rare and often present as look-alikes to many
common childhood conditions, such as jaw or abdominal
swellings and anemia in the case of leukemia, could be even
more challenging. Over or under-diagnosis could have a
large impact on estimation of the incidence of rare cancers.
On the question of whether to establish a BL registry,
Dr. Newton recommended establishing or strengthening
general cancer registries to register all cancers, including
those in children. A general cancer registry would facilitate
the conduct of comparative studies of different cancers
and studies of cancer-specific trends. Since BL in Africa is
strongly associated with Pf malaria, cancer registry stud-
ies could be used to monitor BL trends in relation to
interventions to prevent Pf malaria in holoendemic areas
and thereby provide indirect evidence for the association
between Pf malaria and BL.
Opportunities for African scientists to publish
On behalf of Dr. Franco Buonaguro, Editor-in-Chief
of Infectious Agents and Cancer journal (http://www.
infectagentscancer.com/), Dr. Mbulaiteye described the
importance of scientific publication and encouraged
African scientists to take advantage of open-access
journals. He explained that Infectious Agents and Cancer
journal has prioritized papers reporting data on infectious
agents that cause or are linked to cancer. This focus is
important for Africa where up to one-third of cancers are
caused by infections [45]. Moreover, the open access
policy guarantees that published research can be accessed
immediately via any internet connection. To increase
access to authors from low and middle income countries
(LMICs) and sharpen focus, the journal has added
sections on Clinical Oncology [46] and Cancer Centers in
Resource Limited Settings [47]. In addition, the journal
routinely waives Article Publishing Charges for up to six
articles submitted by scientists from LMICs who lack
grant support for their publication. Finally, he reported
that Thomson Reuters are tracking the journal citations
for “Impact Factor” assessment with expected publication
of results in June 2014. This should further strengthen the
mission of Infectious Agents and Cancer.
Capacity building for cancer research in Africa
Dr. Joe Harford of the NCI presented a talk entitled
“Capacity Building in Africa” that outlined concrete ways
the NCI is supporting cancer research and prevention in
Africa [48]. To overcome the hurdle of preliminary data
from a grant provider’s point of view, which is critical
for funded grants, the NCI has funded through AORTIC
“Beginning Investigator Grants for Catalytic (BIG CAT)”
Research in 2010 to support young researchers in Africa
to conduct studies that could lead to grant applications
by African scientists [26]. Dr. Harford noted that BIG
CAT grants have no categorical exclusions on the type
of cancer research performed (bench, clinical, or epidemio-
logical), but the projects should have a short lifespan (two
years) and should be preliminary in nature. To date, 12
two-year BIG CAT grants have been awarded to African
scientists (Figure 2). The NCI also supports a four-week
Summer Cancer Prevention Fellowship each year in
Bethesda, Maryland, where African scientists (alongside
scientists from all over the world) can learn about cancer
research methods. To date, 118 researchers from Africa
have attended this course, including five who are working
with EMBLEM or affiliated institutions. Finally, the NCI is
funding pilot collaborations between US based cancer
centers and their collaborators in LMICs via supplement
to the P30 core grant of the US based institution.
Future directions: a consortium of Burkitt Lymphoma
studies in Africa
Ms. Detra Robinson from Westat, in Rockville, MD,
discussed the challenges of studying BL, which is a rare
condition. For example, despite the substantial amount of
data reported at the meeting, one of the striking limitations
highlighted was small sample size to obtain robust results.
Other limitations were use of non-uniform methods of case
spotting sample collection, diagnosis and treatment. All
these limitations complicate meaningful comparisons
within and across studies. She noted that the model
adopted by EMBLEM to link multiple sites within and
across several countries is worth considering and, if
possible, expanding. Citing experiences from developed
countries, where large-scale international collaborations
have been established to study rare diseases, Ms. Robinson
advanced the idea that the limitations noted above could be
minimized by forming a consortium of BL research in
Africa. Consortia provide a platform for long-term, large,
well-powered studies. The successful establishment of
EMBLEM in three East African countries increases
our confidence that this type of consortium is possible in
Africa. The consortium would reduce costs of research by
reducing duplication, redundancy, and it would support
linking clinical and basic immunology or molecular studies
to the ongoing epidemiological work. Notwithstanding
the challenges of forming a consortium, including obtain-
ing funding, negotiating intellectual property and publica-
tion rights, and country specific-regulations, the benefits
could be enormous.
Panel discussion
The session ended with a lively panel discussion that
included, among others, Drs. Harford, Newton, Bhatia
and Mbulaiteye, and was moderated by Dr. Simbiri.
Discussion included governance of a BL consortium, the
research questions the consortium would address, and
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advantages of a consortium versus single-center studies.
The multifactorial etiology of BL and its rare occurrence
ensures that no single study will have sufficient expertise or
power to address all the important questions. A consortium
approach would enable faster integration of findings by
providing efficient and cost-effective sharing mechanisms
of research data and samples to a group of otherwise
independent scientists from varying disciplines. Panel
members sought to distinguish between the capability of
collecting data and the necessity for data uniformity. The
issue of coordinating multi-country ethical review board
approvals and risks of delays in implementation and
amendments of protocols was raised. Dr. Harford pointed
out that EMBLEM is a mini-consortium and its experience
of obtaining multi-country ethical review board approvals
suggests that ethical approval and protocol coordination at
a consortium level is possible. He concurred that governing
procedures need to be established early in to manage
expectations and minimize conflict. Dr. Mbulaiteye
explained how EMBLEM has attempted to standardize
research methods across the collaborating sites and he
agreed that obtaining ethical approvals and coordinating
protocol implementation across multiple sites is a challenge
that must (and could) be overcome. Consortii provide
a cost-effective platform for discovery, including in
sub-group analyses. With few opportunities to replicate
findings within a single study, a consortium would provide
a structure for combining many small studies with limited
available data and biospecimens. The consortium could
borrow established procedures for sharing data and samples
and the governance from successful consortia
Dr. Bhatia and Dr. Newton encouraged the BL investiga-
tors to consider extending the consortium to groups outside
Africa, such as Brazil, India, or Papua New Guinea, who
have similar or related research interests. Dr. Newton noted
that the key to collaboration is a willingness to engage and
that was necessary to address the difficulties of establishing
a consortium. If there is an initial willingness to work
together, there can be a consortium. The sentiment was that
there will be challenges at the beginning, but the objective
of forming a consortium is attainable. The critical issues
to be resolved were governance structure, funding, and
harmonization of objectives. On the question of a BL specific
consortium versus an all cancer consortium, Dr. Harford
suggested staying focused and limiting the consortium
to BL. Furthermore, he encouraged the researchers to
define metrics for assessing success, e.g., establishing
a bioinformatics infrastructure or a tissue repository, such
as is being done for the Human Heredity and Health (H3)
African project and nurturing and supporting investiga-
tors to obtain independent funding, such as from the BIG
CAT grants.
Conclusion
The main outcomes of the meeting were improved sharing
of knowledge and experience about ongoing epidemiologic
BL research, BL treatment in different settings, the role of
cancer registries in cancer research, and opportunities for
Figure 2 Maps showing countries from which Letters of Intent (LOI’s) were received for Beginning Investigator Grants for Catalytic
research (BIG Cat). The BIG Cat initiative is overseen by the African Organization for Research and Training in Cancer (AORTIC) with funding to
date having been provided by the U.S. National Cancer Institute. The application process involves submission of a LOI followed by a request for
and submission of a full project proposal. One review criteria for applications is relevance to the cancer burden of Africa. Between Cohort #1
(2011) and Cohort #2 (2013), awareness of this funding opportunity increased as reflected in the number of LOI’s received as well as countries
represented by the applicants.
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African scientists to publish in scientific journals. The idea
of forming a consortium of BL to improve coordination,
information sharing, accelerate discovery, dissemination,
and translation of knowledge and to build capacity, while
reducing redundant efforts, was discussed.
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